SCHEMBL2192260

SCHEMBL2192260

NCCCC[C@H](N)C(=O)N[C@H]([C]=O)CS

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
DPP8 Q6V1X1 5/20 0.47
DPP9 Q86TI2 5/20 0.47
DPP7 Q9UHL4 5/20 0.47
GSR P00390 1/20 0.44
GNAI3 P08754 1/20 0.43
GNAO1 P09471 1/20 0.43
GNAI1 P63096 1/20 0.43
DPP4 P27487 2/20 0.41
CPB2 Q96IY4 3/20 0.40
MMP2 P08253 2/20 0.38
RNPEP Q9H4A4 1/20 0.36
TERT O14746 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28069698 0.95 DPP7 (0.46) DPP8DPP9DPP7GSRGNAI3
SCHEMBL2183058 0.89 DPP8 (0.42) DPP8DPP9DPP7GSRGNAI3
SCHEMBL7751944 0.89 DPP7 (0.50) DPP8DPP9DPP7GSRGNAI3
SCHEMBL7751947 0.89 DPP7 (0.50) DPP8DPP9DPP7GSRGNAI3
SCHEMBL8495681 0.83 DPP7 (0.56) DPP8DPP9DPP7GSRGNAI3
SCHEMBL2183995 0.82 NPY4R (0.46) DPP8DPP9DPP7GNAI3GNAO1
SCHEMBL1651538 0.82 DPP8 (0.48) DPP8DPP9DPP7GSRGNAI3
SCHEMBL2192330 0.82 DPP8 (0.45) DPP8DPP9DPP7GSRGNAI3
SCHEMBL8567236 0.82 FOLH1 (0.47) DPP8DPP9DPP7GSRGNAI3
SCHEMBL1888867 0.82 FOLH1 (0.47) DPP8DPP9DPP7GSRGNAI3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190070251-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NEKTAR THERAPEUTICS 2019-03-07 US disclosed
US-9682153-B2 Polymer conjugates of therapeutic peptides NEKTAR THERAPEUTICS (US) 2017-06-20 US disclosed
US-20160022828-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NEKTAR THERAPEUTICS 2016-01-28 US disclosed
US-20110171312-A1 MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE NEKTAR THERAPEUTICS (US) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160022828-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NGLY1, CD44, IAPP DPP8 644/4885DPP9 996/4885DPP7 450/4885
US-20190070251-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NGLY1, CD44, IAPP DPP8 644/4885DPP9 996/4885DPP7 450/4885
US-20110171312-A1 MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE DNPEP, VIP, PTMS DPP8 590/4885DPP9 903/4885DPP7 594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.